CD19 and acute lymphoblastic leukemia: Therefore, in this study, we evaluated the efficacy of CIMLNK in combination with the anti-CD19 monoclonal antibody Tafasitamab (TAFA) as a novel immunotherapeutic approach against CD19+ B-ALL.